EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma

On May 20, 2016, a conditional marketing authorization valid through the European Union (EU) was issued for daratumumab as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory d...

Descripción completa

Detalles Bibliográficos
Autores principales: Tzogani, Kyriaki, Penninga, Elisabeth, Schougaard Christiansen, Marie Louise, Hovgaard, Doris, Sarac, Sinan B., Camarero Jimenez, Jorge, Garcia, Isabel, Lafuente, Marta, Sancho‐López, Arantxa, Salmonson, Tomas, Gisselbrecht, Christian, Pignatti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Regulatory Issues: EMA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947446/
https://www.ncbi.nlm.nih.gov/pubmed/29371479
http://dx.doi.org/10.1634/theoncologist.2017-0328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947446/
https://www.ncbi.nlm.nih.gov/pubmed/29371479
http://dx.doi.org/10.1634/theoncologist.2017-0328

Ejemplares similares